Comparison of PGV and GV regimen in treatment of advanced non-small cell lung cancer
Lists
Only you see this
Abstract
Objective:From January 2000 to December 2002, three-drug, platinum-based regimen(PGV): [cisplatin (DDP) + gemcitabine (GEM) +vinorelbine (VNB) ] and two-drug combination without a platinum drug (GV): [gemcitabine (GEM) + vinorelbine (VNB)] had been used to treat 55 patients with advanced non-small cell lung cancer (NSCLC). The response and major adverse reaction were analyzed and compared.Methods:Twenty-four cases of advanced NSCLC (stageⅢ~Ⅳ) patients were treated with PGV (DDP 35mg/m2 d_1~d_3; GEM 1 250mg/m2 d_1,d_8). The other 31 cases were treated with GV (GEM 1 250mg/m2 d_1,d_8; VNB 25mg/m2 d_1,d_8). The two regimens were repeated every 3 weeks for 6 courses.Results:In PGV group, the overall response rate was 45.8% (CR+PR=11), medium response time was 5.5 months, medium survival time was 11 months and 1-year survival rate 41.7%. In GV group, the overall response rate was 48.4% (CR+PR=15), medium response time, survival time and 1-year survival rate were 6.5, 10 months and 41.9%, respectively. The major toxicities were nausea/vomiting, myelosuppression in PGV group, myelosuppression and phlebitis in GV group, respectively.Conclusion:PGV and GV regimen for advanced NSCLC have similar response rate (P0.05). Two-drug combination without a platinum drug is less toxic than three-drug, platinum-based regimen. GV can be used as first-line treatment of advanced NSCLC.
BibTeX
@inproceedings{wang2006comparison,
author = {Wenwu Wang},
title = {{Comparison of PGV and GV regimen in treatment of advanced non-small cell lung cancer}},
booktitle = {Chinese},
year = {2006},
}Loading related content...